title: Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats.
abstract: 1. Isoarecolone was approximately 250 times less potent than nicotine as an inhibitor of [3H]-nicotine binding to rat brain membranes. Isoarecolone failed to inhibit the binding of the nicotinic ligand [125I]-alpha-bungarotoxin or of the muscarinic ligand [3H]-QNB. 2. Nicotine (0.01-30 microM) evoked the release of [3H]-dopamine from striatal and frontal cortex synaptosomes, with EC50 values of approximately 0.5 microM in each case. This release was largely mecamylamine-sensitive. 3. Isoarecolone (1-200 microM) evoked predominantly mecamylamine-sensitive dopamine release from both striatal and cortical synaptosomes, with a potency at least 20 times less than that of nicotine. The maximum effect of isoarecolone was less than that of nicotine, particularly in the frontal cortex preparation. 4. In control rats treated chronically with saline, neither nicotine nor isoarecolone had clear effects on locomotor activity at the doses tested. Chronic treatment with nicotine clearly sensitized rats to the locomotor activating effect of isoarecolone was seen at a dose about 40 times larger than that of nicotine. 5. The low potency and efficacy of isoarecolone in facilitating sensitized locomotor activity resembled its lower potency and efficacy, compared with nicotine, in evoking dopamine release in vitro. The agonist profile of the nicotinic receptor population mediating dopamine release may determine the pharmacological characteristics of consequent locomotor behaviour.
authors.affiliation: School of Biology and Biochemistry, University of Bath.
authors.forename: P
authors.initials: P
authors.lastname: Whiteaker
authors.forename: H S
authors.initials: HS
authors.lastname: Garcha
authors.forename: S
authors.initials: S
authors.lastname: Wonnacott
authors.forename: I P
authors.initials: IP
authors.lastname: Stolerman
mesh_terms: D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001115:Arecoline / Q000031:analogs & derivatives* / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D004347:Drug Interactions; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
chemical_list: D015259:Dopamine Agents; D018722:Nicotinic Agonists; C095493:isoarecolone; D001115:Arecoline; D009538:Nicotine; D000661:Amphetamine; D004298:Dopamine